Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of BNT162b2 booster after AZD1222 in elderly and adults with underlying diseases (standard vs low dose, intramuscular)
TCTR20211027002Phase 2Completed
- Sponsor
- National Vaccine Institute
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by National Vaccine Institute. Started Nov 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20211027002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211027002.